118 related articles for article (PubMed ID: 12111990)
1. Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer.
Leman ES; Arlotti JA; Dhir R; Greenberg N; Getzenberg RH
J Cell Biochem; 2002; 86(2):203-12. PubMed ID: 12111990
[TBL] [Abstract][Full Text] [Related]
2. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer.
Leman ES; Madigan MC; Brünagel G; Takaha N; Coffey DS; Getzenberg RH
J Cell Biochem; 2003 Feb; 88(3):599-608. PubMed ID: 12532335
[TBL] [Abstract][Full Text] [Related]
3. Nuclear matrix proteins as biomarkers in prostate cancer.
Leman ES; Getzenberg RH
J Cell Biochem; 2002; 86(2):213-23. PubMed ID: 12111991
[TBL] [Abstract][Full Text] [Related]
4. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
[TBL] [Abstract][Full Text] [Related]
5. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer.
Alberti I; Barboro P; Barbesino M; Sanna P; Pisciotta L; Parodi S; Nicolò G; Boccardo F; Galli S; Patrone E; Balbi C
J Cell Biochem; 2000 Sep; 79(3):471-85. PubMed ID: 10972984
[TBL] [Abstract][Full Text] [Related]
6. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
7. Identification of nuclear matrix proteins in the cancer and normal rat prostate.
Getzenberg RH; Pienta KJ; Huang EY; Coffey DS
Cancer Res; 1991 Dec; 51(24):6514-20. PubMed ID: 1742724
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
10. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
11. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
12. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer.
Partin AW; Getzenberg RH; CarMichael MJ; Vindivich D; Yoo J; Epstein JI; Coffey DS
Cancer Res; 1993 Feb; 53(4):744-6. PubMed ID: 7679049
[TBL] [Abstract][Full Text] [Related]
13. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
14. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model.
Duan W; Gabril MY; Moussa M; Chan FL; Sakai H; Fong G; Xuan JW
Oncogene; 2005 Feb; 24(9):1510-24. PubMed ID: 15674347
[TBL] [Abstract][Full Text] [Related]
15. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.
Partin AW; Briggman JV; Subong EN; Szaro R; Oreper A; Wiesbrock S; Meyer J; Coffey DS; Epstein JI
Urology; 1997 Nov; 50(5):800-8. PubMed ID: 9372899
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
18. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
Suttie AW; Dinse GE; Nyska A; Moser GJ; Goldsworthy TL; Maronpot RR
Toxicol Pathol; 2005; 33(3):386-97. PubMed ID: 15805078
[TBL] [Abstract][Full Text] [Related]
19. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Yeh IT; Reddick RL; Kumar AP
Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
[TBL] [Abstract][Full Text] [Related]
20. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.
Kasper S
J Cell Biochem; 2005 Feb; 94(2):279-97. PubMed ID: 15565647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]